**Background**

Combinations of ICIs and chemotherapy are approved for the treatment of patients with advanced NSCLC, regardless of PD-L1 expression. However, a large proportion of patients do not respond to bevacizumab + chemotherapy.

**Methods**

INTR@PID LUNG 024 (ACTUATION); bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC regardless of PD-L1 expression status

**Results**

Here we report overall safety from the ongoing INTR@PID LUNG 024 study, which represents the first report of safety results from a clinical trial with a bintrafusp alfa 300 mg Q4W regimen

**Conclusions**

- The combination of bintrafusp alfa 2400 mg with chemotherapy was well tolerated
- No new safety signals were identified, and there were no treatment-related deaths
- The safety profile of bintrafusp alfa in combination with chemotherapy was similar to that reported for ICIs in combination with chemotherapy, except for TGF-β–related skin lesions, which are anticipated with TGF-β inhibition